Promitil

Other Medications

Experimental

Not available 1 Clinical Trials

Description

Promitil is an experimental medication currently being studied in clinical trials for various types of cancer, including colorectal cancer. It is a type of liposomal drug, meaning the medication is packaged inside tiny fat-like particles (liposomes) designed to deliver it to the tumor. In the clinical trials for colorectal cancer, Promitil has been tested alone and in combination with other treatments like bevacizumab (Avastin) and capecitabine (Xeloda). The trials are primarily in Phase 1, which means they are focused on determining the safety and appropriate dosage of the drug in a small group of patients. The trials also look for early signs of effectiveness. Promitil is not yet approved for treating colorectal cancer.

Mechanism of Action

Promitil is a pegylated liposomal formulation of mitomycin-C, which is a chemotherapy drug. The liposome acts as a carrier to potentially deliver the mitomycin-C more effectively to cancer cells. The specific way Promitil works to target cancer cells is still being investigated in clinical trials. It is designed to release mitomycin-C, which then interferes with the DNA of cancer cells, preventing them from growing and dividing.

Side Effects

As Promitil is an experimental drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. Side effects observed in early trials for other cancers might include infusion-related reactions (like fever Chills Nausea) Fatigue Low blood counts (which can increase risk of infection or bleeding) And other common chemotherapy side effects. Patients participating in the trials are closely monitored for any adverse events. Specific side effect data from the colorectal cancer trials are not yet fully available.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01705002 Phase 1

Archived

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

Israel

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.